FDA generic-drugs chief resigns

03/14/2013 | Pharmalot.com

Dr. Greg Geba announced he will resign as director of the FDA's Office of Generic Drugs, just as the FDA has started collecting generic-drug manufacturer user fees and two months before the office is scheduled to be elevated. Dr. Janet Woodcock, director of the Center for Drug Evaluation & Research, will temporarily cover Geba's duties.

View Full Article in:

Pharmalot.com